CN105228602A - 使用薄荷醇、芳樟醇和/或冰素治疗或预防神经变性障碍 - Google Patents

使用薄荷醇、芳樟醇和/或冰素治疗或预防神经变性障碍 Download PDF

Info

Publication number
CN105228602A
CN105228602A CN201480029668.7A CN201480029668A CN105228602A CN 105228602 A CN105228602 A CN 105228602A CN 201480029668 A CN201480029668 A CN 201480029668A CN 105228602 A CN105228602 A CN 105228602A
Authority
CN
China
Prior art keywords
compositions
linalool
menthol
disease
neural degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480029668.7A
Other languages
English (en)
Chinese (zh)
Inventor
S·卡马乔
S·米奇里格冈萨雷斯
J·勒库特
H·马克莱姆
M·派佐里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Societe dAssistance Technique pour Produits Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe dAssistance Technique pour Produits Nestle SA filed Critical Societe dAssistance Technique pour Produits Nestle SA
Publication of CN105228602A publication Critical patent/CN105228602A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02—Acyclic alcohols with carbon-to-carbon double bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C35/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic
    • C07C35/08—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring monocyclic containing a six-membered rings
    • C07C35/12—Menthol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480029668.7A 2013-05-24 2014-05-23 使用薄荷醇、芳樟醇和/或冰素治疗或预防神经变性障碍 Pending CN105228602A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361827243P 2013-05-24 2013-05-24
US61/827,243 2013-05-24
PCT/EP2014/060632 WO2014187942A1 (en) 2013-05-24 2014-05-23 Treatment or prevention of neurodegenerative disorders using menthol, linalool and/or icilin

Publications (1)

Publication Number Publication Date
CN105228602A true CN105228602A (zh) 2016-01-06

Family

ID=50819727

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480029668.7A Pending CN105228602A (zh) 2013-05-24 2014-05-23 使用薄荷醇、芳樟醇和/或冰素治疗或预防神经变性障碍

Country Status (8)

Country Link
US (1) US20160108004A1 (enExample)
EP (1) EP3003291A1 (enExample)
JP (1) JP2016524608A (enExample)
CN (1) CN105228602A (enExample)
AU (1) AU2014270338A1 (enExample)
BR (1) BR112015028516A2 (enExample)
CA (1) CA2908402A1 (enExample)
WO (1) WO2014187942A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107789349A (zh) * 2017-12-01 2018-03-13 新乡医学院 治疗阿尔海默氏综合症的药物组合物及其应用
CN109674851A (zh) * 2017-10-18 2019-04-26 大江生医股份有限公司 薄荷精油的应用
CN116018134A (zh) * 2020-03-24 2023-04-25 洪明奇 薄荷醇用于制备治疗神经退化症及中风的外用组合物的用途
CN116249456A (zh) * 2020-10-21 2023-06-09 三井农林株式会社 脑机能改善剂

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6719574B2 (ja) 2016-02-22 2020-07-08 ニュートリシャス ベー．フェー．Ｎｅｗｔｒｉｃｉｏｕｓ Ｂ．Ｖ． 神経変性疾患の、予防または治療のための組成物
CA3039413A1 (en) * 2016-10-11 2018-04-19 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of neurodegenerative diseases
CN116919930A (zh) * 2022-04-06 2023-10-24 沈阳药科大学 萜类化合物在调节脑膜淋巴循环促进脑内异常蛋白通过淋巴途径清除中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177472B1 (en) * 1995-08-08 2001-01-23 University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease proteins and uses thereof
CN102083444A (zh) * 2008-05-09 2011-06-01 西奈山医学院 用于预防和治疗神经退行性疾病的方法
KR20110134961A (ko) * 2010-06-10 2011-12-16 고려대학교 산학협력단 리나룰을 포함하는 중추신경계 장애의 예방, 치료, 또는 개선용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4742204B2 (ja) * 2005-01-21 2011-08-10 財団法人ヒューマンサイエンス振興財団 脂肪細胞分化制御剤
JP2007302572A (ja) * 2006-05-09 2007-11-22 Pokka Corp 脳機能改善剤及びそれを含有する脳機能改善組成物
JP2008231049A (ja) * 2007-03-22 2008-10-02 Saburo Yasuda アポトーシス誘導物質
KR20090085237A (ko) * 2008-02-04 2009-08-07 김병문 천연 진주가루를 함유한 뇌질환 예방 및 치료용 한약조성물
KR20120103317A (ko) * 2011-03-10 2012-09-19 한국생명공학연구원 아실 코에이:콜레스테롤 아실트랜스퍼라제 저해활성을 갖는 고수씨 추출물 또는 이로부터 분리된 리나로올을 포함하는 조성물
WO2013168090A1 (en) * 2012-05-07 2013-11-14 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Researc Organization (Aro) (Volcanii Center). Geranium oil and constituents thereof for treatment of neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177472B1 (en) * 1995-08-08 2001-01-23 University Of Alabama At Birmingham Research Foundation Regulation of alzheimer's disease proteins and uses thereof
CN102083444A (zh) * 2008-05-09 2011-06-01 西奈山医学院 用于预防和治疗神经退行性疾病的方法
KR20110134961A (ko) * 2010-06-10 2011-12-16 고려대학교 산학협력단 리나룰을 포함하는 중추신경계 장애의 예방, 치료, 또는 개선용 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANDREA M. VINCENT等: "Identification of candidate drugs for the treatment of ALS", 《AMYOTROPHIC LATERAL SCLEROSIS》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109674851A (zh) * 2017-10-18 2019-04-26 大江生医股份有限公司 薄荷精油的应用
CN107789349A (zh) * 2017-12-01 2018-03-13 新乡医学院 治疗阿尔海默氏综合症的药物组合物及其应用
CN116018134A (zh) * 2020-03-24 2023-04-25 洪明奇 薄荷醇用于制备治疗神经退化症及中风的外用组合物的用途
CN116249456A (zh) * 2020-10-21 2023-06-09 三井农林株式会社 脑机能改善剂

Also Published As

Publication number Publication date
EP3003291A1 (en) 2016-04-13
AU2014270338A1 (en) 2015-10-08
WO2014187942A1 (en) 2014-11-27
US20160108004A1 (en) 2016-04-21
JP2016524608A (ja) 2016-08-18
CA2908402A1 (en) 2014-11-27
BR112015028516A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
CN105228602A (zh) 使用薄荷醇、芳樟醇和/或冰素治疗或预防神经变性障碍
EP1997496B1 (en) Composition containing riboflavin and sesamin-class compounds
AU2019222781B2 (en) Treatment or prevention of non-inflammatory neuronal damage from brain trauma and strokes using Menthol, Linalool and/or Icilin
WO2022090734A1 (en) Neurodegenerative treatment
US20160108005A1 (en) Treatment or prevention of depression using menthol and/or icilin
US11241433B2 (en) Treatment or prevention of autism disorders using menthol, linalool and/or icilin
CN105792819A (zh) 使用肉桂醛增加能量消耗的方法和组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160106